FDA Expedited IND Pilot Targets Faster First-In-Human Trials
The FDA’s Expedited IND Pilot introduces rolling review and sponsor-QRI partnerships to accelerate Phase I first-in-human trials while retaining regulatory oversight.
The FDA Expedited IND Pilot introduces a new model for preparing first-in-human clinical trials in the United States. By combining sponsor expertise with Qualified Research Institutions and rolling regulatory review, the pilot aims to identify issues earlier without reducing FDA oversight.
FDA Expedited IND Pilot Changes the Pre-IND Model
The U.S. Food and Drug Administration (FDA) launched its final Expedited Investigational New Drug (IND) Pilot on 15 September 2026. Applications are open until 30 October 2026, with the agency expecting to select eight to 10 sponsor-QRI pairs for the initial cohort.
The pilot sits within the HHS Operation TrialBlazer and focuses on the period before a formal Phase I IND enters its 30-day review.
The objective is practical, entailing reducing avoidable delays between IND preparation and first-in-human (FIH) trial initiation.
Under the model, drug sponsors work with Qualified Research Institutions (QRIs). These can include academic medical centres, healthcare networks, contract research organisations, regulatory advisers, and other research organisations with relevant scientific expertise.
The QRI can provide expert input across pharmacology and toxicology, clinical development, and chemistry, manufacturing, and controls (CMC). This creates an additional layer of scientific review before the complete IND reaches the formal review stage.
Rolling Review Includes Regulatory Work Earlier
The most significant change is the rolling submission model.
Rather than waiting until every IND component is complete, participating sponsors can submit individual components as they become ready during the pre-IND phase.
The FDA reviewers can then identify questions or deficiencies earlier in development.
This matters because a problem discovered late in IND preparation can affect multiple downstream activities. Resolving it earlier can help sponsors avoid rework and reduce the risk of delays once the formal submission process begins.
The pilot also encourages coordination with activities that can progress alongside IND development, including Institutional Review Board review and clinical trial site activation where appropriate.
The intent is to reduce idle time across the development workflow, rather than simply accelerate the FDA review clock.
The formal 30-day IND review does not disappear. The FDA continues to determine whether a clinical investigational trial can proceed and whether a clinical hold is required.
Maximise Pharma Innovation With Quality-by-Design
Find out how Quality-by-Design improves reliability and compliance in pharma and how you can maximise innovation through quality-based pharma development systems.
What do Sponsors Need to Know About the FDA Expedited IND Pilot?
The expedited IND pilot is selective rather than a general alternative to the existing IND pathway.
The FDA will prioritise novel product candidates intended for commercial development, targeting a Phase I FIH IND in the United States where the investigational product has no existing clinical experience.
Sponsors also need sufficient preliminary nonclinical information to support assessment of the proposed development and IND timeline.
The agency will consider public health impact, unmet medical need, sponsor experience, and portfolio diversity. Rare diseases, paediatric indications, novel modalities, and underrepresented therapeutic areas may contribute to cohort diversity.
Sponsors and prospective QRIs must apply as a pair. The parties establish their relationship independently of the FDA, while FDA evaluates the combined application.
For sponsors, this places greater emphasis on early regulatory planning, cross-functional readiness, and QRI selection.
The value of the model will depend not only on faster submission activity, but also on the quality of scientific judgement brought into the process.
Why the Expedited IND Pilot Matters for Drug Development
The Expedited IND Pilot is important because it tests whether regulatory efficiency can come from better coordination before formal review, rather than simply shortening review periods.
That matters for pharmaceutical companies managing complex development programmes. A faster pathway is only useful if it preserves scientific quality and patient protection.
The FDA has also stated that the pilot will generate evidence for potential future approaches to early-stage development. One possibility identified by the agency is a future accreditation model for QRIs with demonstrated scientific and regulatory judgement.
The pilot therefore represents more than a temporary submission mechanism. It is also a policy experiment in how sponsors, specialist institutions, and regulators could share expertise earlier in the drug development lifecycle.
For organisations preparing future FIH programmes, the immediate priority is to understand the eligibility criteria, identify appropriate QRI capabilities, and assess whether earlier scientific review could materially improve programme readiness.
What Comes Next for FDA Expedited IND?
Applications close on 30 October 2026, with the FDA currently targeting 18 December for cohort selection. Sponsors that are not selected can continue using existing regulatory interactions, including INTERACT and Pre-IND meetings.
The pilot’s longer-term value will depend on measurable outcomes. Key questions include whether rolling review reduces avoidable rework, whether issues are resolved earlier, and whether the model shortens the overall path to FIH trials without weakening regulatory standards.
The FDA Expedited IND Pilot puts early regulatory readiness at the centre of clinical development. Its results could help shape how FIH programmes are prepared and reviewed in the years ahead.
At Pharmatica, we track the regulatory, scientific, and operational changes reshaping pharmaceutical development. Our Insights connect policy with the practical decisions that influence R&D strategy, clinical readiness, and market access.
Pharmatica: Insight. Connection. Impact.
Frequently Asked Questions
What is the FDA Expedited IND Pilot?
The FDA Expedited IND Pilot is a programme designed to test faster approaches to preparing and reviewing Phase I first-in-human IND submissions while maintaining FDA safety and scientific oversight.
What is a Qualified Research Institution?
A Qualified Research Institution is a specialist organisation that partners with a drug sponsor to provide scientific and regulatory expertise during IND preparation.
What is rolling IND submission?
Rolling IND submission allows participating sponsors to provide individual IND components to the FDA as they become ready during the pre-IND phase, rather than waiting for the complete package.
Who can apply for the Expedited IND Pilot?
Commercial drug sponsors developing novel products for a U.S. Phase I first-in-human trial can apply with a prospective Qualified Research Institution, subject to FDA eligibility and selection criteria.
When is the FDA Expedited IND Pilot application deadline?
The FDA is accepting applications until 30 October 2026 and expects to select eight to 10 sponsor-QRI pairs for the initial pilot cohort.
About the author
Did you enjoy the content?
Why not support Nicole Dale by giving this content a like
Comments (0)